use advanced technology to make informed decisions

MammaPrint + BluePrint: Better Together.

Together, uncovers more clinically actionable biology

effective cancer management depends upon an accurate prognosis and treatment prediction.
  • NBRST Study Results using BluePrint Molecular Subtyping

    Dr. Pat Whitworth, MD, discusses the results of the NBRST study showing how BluePrint Molecular Subtyping more accurately identified patients who may benefit from neoadjuvant chemotherapy

    Share This Video

    NBRST Study Results using BluePrint Molecular Subtyping

    Dr. Pat Whitworth, MD, discusses the results of the NBRST study showing how BluePrint Molecular Subtyping more accurately identified patients who may benefit from neoadjuvant chemotherapy

    Share This Video

  • Benefits of MammaPrint and BluePrint on treatment decisions for breast cancer

    Dr. Massimo Cristofanilli, MD discusses the benefits of using the MammaPrint® 70-Gene assay and the BluePrint® 80-Gene assay in the treatment process for breast cancer.

    Share This Video

    Benefits of MammaPrint and BluePrint on treatment decisions for breast cancer

    Dr. Massimo Cristofanilli, MD discusses the benefits of using the MammaPrint® 70-Gene assay and the BluePrint® 80-Gene assay in the treatment process for breast cancer.

    Share This Video

  • Using Molecular Subtypes to more accurately predict response to therapies

    Dr. Stephan Glück, MD, discusses the results of his study where BluePrint® molecular subtyping more accurately identifies cancer subtypes with distinct improvements in pCR with neoadjuvant chemotherapy

    Share This Video

    Using Molecular Subtypes to more accurately predict response to therapies

    Dr. Stephan Glück, MD, discusses the results of his study where BluePrint® molecular subtyping more accurately identifies cancer subtypes with distinct improvements in pCR with neoadjuvant chemotherapy

    Share This Video

  • Breast cancer is heterogeneous disease

    Dr. Rene Bernards, PhD, co-developer of MammaPrint® discusses how breast cancer biology drove the discovery of the 70-Gene Breast Cancer Recurrence Assay

    Share This Video

    Breast cancer is heterogeneous disease

    Dr. Rene Bernards, PhD, co-developer of MammaPrint® discusses how breast cancer biology drove the discovery of the 70-Gene Breast Cancer Recurrence Assay

    Share This Video

  • UPMC study results at ASCO 2014

    Dr. Adam Brufsky, MD, PhD, discusses a study comparing MammaPrint® to the 21-gene assay and how BluePrint® molecular subtyping compares to traditional subtyping.

    Share This Video

    UPMC study results at ASCO 2014

    Dr. Adam Brufsky, MD, PhD, discusses a study comparing MammaPrint® to the 21-gene assay and how BluePrint® molecular subtyping compares to traditional subtyping.

    Share This Video

  • Personalizing Breast Cancer treatment with MammaPrint and BluePrint

    Learn how Dr. Juliann Reiland, MD uses MammaPrint and BluePrint to tailor breast cancer treatment decisions

    Share This Video

    Personalizing Breast Cancer treatment with MammaPrint and BluePrint

    Learn how Dr. Juliann Reiland, MD uses MammaPrint and BluePrint to tailor breast cancer treatment decisions

    Share This Video

  • Dr. John Link, MD

    No two tumors are alike.

    Why should they be treated the same?

    Share This Video

    Dr. John Link, MD

    No two tumors are alike.

    Why should they be treated the same?

    Share This Video

  • MammaPrint's definitive answers help guide treatment for ambiguous intermediate results

    Dr. Wallentine, MD shares a story about how MammaPrint’s definitive results helped spare a patient from unnecessary chemotherapy

    Share This Video

    MammaPrint's definitive answers help guide treatment for ambiguous intermediate results

    Dr. Wallentine, MD shares a story about how MammaPrint’s definitive results helped spare a patient from unnecessary chemotherapy

    Share This Video

Mammaprint

BluePrint

Online Portal